Palvella Therapeutics Q3 net loss widens on higher costs

Overview

• US rare skin disease drug developer's Q3 net loss widened yr/yr on higher R&D and admin costs

• Company had $236.7 mln in cash, cash equivalents and short-term investments at quarter end

• FDA accepted NDA for QTORIN rapamycin, grants priority review with Feb 2027 target action date

Outlook

• Company preparing for standalone U.S. commercial launch of QTORIN rapamycin in H1 2027, if approved

• Phase 3 trial of QTORIN rapamycin for cutaneous venous malformations expected to begin in Q4 2026

• Topline results from Phase 2 LOTU trial in angiokeratomas expected in H2 2027

Result Drivers

• R&D SPENDING - Higher research and development expenses driven by increased manufacturing activity, clinical development for angiokeratomas, NDA submission costs, and increased headcount and consulting services

• ADMINISTRATIVE COSTS - Higher general and administrative expenses due to increased headcount and professional services related to operating as a public company

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 17 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Palvella Therapeutics Inc is $229.00, about 41.1% above its November 4 closing price of $162.28

Reuters Recommended Reads

• Nov 2 - FDA to review uniQure's Huntington's gene therapy, decision due on May 2027

• Nov 3 - Rhythm Pharma Q3 net loss narrower than estimated on IMCIVREE demand

• Nov 4 - Kailera Therapeutics Q3 net loss widens on higher R&D costs

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)